Stock Screener App

Frei -

Installieren

Drug Manufacturers - General

122.17

0.06% 0.1164

Gilead Sciences Inc (GILD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GILD? Forum Prognose Aktiensplit Dividendenhistorie

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

Truist Financial Reaffirms Buy Rating for Gilead Sciences (NASDAQ:GILD) - MarketBeat

HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline - TradingView

21,000 Shares in Gilead Sciences, Inc. $GILD Acquired by Hussman Strategic Advisors Inc. - MarketBeat

Sigma Planning Corp Sells 12,373 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. (GILD) Stock Forecasts - Yahoo! Finance Canada

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Applying chart zones and confluence areas to Gilead Sciences Inc.July 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com

Real time alert setup for Gilead Sciences Inc. performance2025 Top Decliners & Step-by-Step Swing Trade Plans - newser.com

Gilead Sciences, Inc. (GILD.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 - The Joplin Globe

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire Inc.

Bernstein reiterates Gilead stock rating at Outperform on strong HIV core - Investing.com Nigeria

iA Global Asset Management Inc. Acquires 6,297 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Stake Decreased by Hunter Associates Investment Management LLC - MarketBeat

Gilead Sciences, Inc. $GILD Shares Sold by South Dakota Investment Council - MarketBeat

2,128 Shares in Gilead Sciences, Inc. $GILD Purchased by Elm Partners Management LLC - MarketBeat

Spire Wealth Management Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

What candlestick patterns are forming on Gilead Sciences Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com

Is Gilead Sciences Inc. stock cheap at current valuationJobs Report & Accurate Technical Buy Alerts - newser.com

Longbow Finance SA Purchases 9,390 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Will Gilead Sciences Inc. outperform the marketWeekly Profit Report & Growth Focused Entry Reports - newser.com

Syverson Strege & Co Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat

NWK Group Inc. Has $7.33 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Shares Bought by Assetmark Inc. - MarketBeat

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2025 Earnings Call Transcript - Insider Monkey

Gilead Sciences, Inc. (GILD) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia

Gilead Sciences, Inc. (GILD) Stock forecasts - Yahoo! Finance UK

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat

Gilead Sciences (GILD) Margin Recovery Reinforces Bullish Narrative With 6,336% Earnings Growth - Sahm

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $105.00 at Royal Bank Of Canada - MarketBeat

Gilead Sciences' (GILD) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Morgan Stanley Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $147.00 - MarketBeat

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00 - MarketBeat

Gilead Sciences, Inc. (NASDAQ:GILD) Plans $0.79 Quarterly Dividend - MarketBeat

Gilead Sciences (NASDAQ:GILD) Given New $110.00 Price Target at The Goldman Sachs Group - MarketBeat

Gilead Sciences (NASDAQ:GILD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq

Fisher Funds Management LTD Reduces Position in Gilead Sciences, Inc. $GILD - MarketBeat

Atria Investments Inc Purchases 14,392 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Price momentum metrics for Gilead Sciences Inc. explainedTrade Analysis Report & Proven Capital Preservation Methods - newser.com

JP Morgan Raises Gilead Sciences (GILD) Price Target to $150 | G - GuruFocus

Gilead Sciences (NASDAQ:GILD) Posts Quarterly Earnings Results - MarketBeat

Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround - Yahoo Finance

Gilead Sciences’ Earnings Call Highlights Growth and Optimism - TipRanks

Needham Reiterates Gilead Sciences (GILD) Buy Recommendation - Nasdaq

Gilead Sciences (NASDAQ:GILD) Updates FY 2025 Earnings Guidance - MarketBeat

Gilead Stock Reverses; Why Its New HIV Shot Looks Better - Investor's Business Daily

Research Alert: CFRA Keeps Buy Rating On Shares Of Gilead Sciences, Inc. - 富途牛牛

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Benzinga

RBC Capital Maintains Gilead Sciences (GILD) Rating, Raises Pric - GuruFocus

Gilead's long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales - Fierce Pharma

Gilead Sciences: Strong Performance and Future Potential Drive Buy Rating - TipRanks

Gilead's Cell Therapy Portfolio Slumps in Q3, but Firm Still Optimistic About In Vivo Opportunities - Precision Medicine Online

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow - TradingView

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - Enidnews.com

Does Gilead Sciences Offer Strong Value After Breakthroughs in Antiviral Treatments? - simplywall.st

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir) - BioSpace

Gilead GILD Q3 2025 Earnings Call Transcript - AOL.com

Gilead Sciences (GILD) Maintains Dividend, Adjusts 2025 Outlook - GuruFocus

Gilead Sciences (GILD) Acquires Key Assets from HOOKIPA Pharma - GuruFocus

Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences - MarketScreener

Gilead 3rd-qtr EPS beats expectations - The Pharma Letter

GILD Receives 'Buy' Rating Reiteration from Needham | GILD Stock News - GuruFocus

GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds - Yahoo Finance

Impact Partnership Wealth LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

HOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead Sciences - Quiver Quantitative

AMGN

$296.81

0.08%

NVO

$48.37

1.59%

PFE

$24.21

1.80%

SNY

$49.39

1.30%

MRK

$83.75

1.39%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters